School of Medicine


Showing 11-20 of 52 Results

  • Dean W. Felsher

    Dean W. Felsher

    Professor of Medicine (Oncology) and of Pathology

    Current Research and Scholarly Interests My laboratory investigates how oncogenes initiate and sustain tumorigenesis. I have developed model systems whereby I can conditionally activate oncogenes in normal human and mouse cells in tissue culture or in specific tissues of transgenic mice. In particular using the tetracycline regulatory system, I have generated a conditional model system for MYC-induced tumors. I have shown that cancers caused by the conditional over-expression of the MYC proto-oncogene regress with its inactivation.

  • George A. Fisher Jr.

    George A. Fisher Jr.

    Colleen Haas Chair in the School of Medicine

    Current Research and Scholarly Interests Clinical expertise in GI cancers with research which emphasizes Phase I and II clinical trials of novel therapies but also includes translational studies including biomarkers, molecular imaging, tumor immunology and development of immunotherapeutic trials.

  • James Ford

    James Ford

    Professor of Medicine (Oncology) and of Genetics and, by courtesy, of Pediatrics

    Current Research and Scholarly Interests Mammalian DNA repair and DNA damage inducible responses; p53 tumor suppressor gene; transcription in nucleotide excision repair and mutagenesis; genetic determinants of cancer cell sensitivity to DNA damage; genetics of inherited cancer susceptibility syndromes and human GI malignancies; clinical cancer genetics of BRCA1 and BRCA2 breast cancer and mismatch repair deficient colon cancer.

  • Kristen N Ganjoo

    Kristen N Ganjoo

    Associate Professor of Medicine (Oncology) at the Stanford University Medical Center

    Current Research and Scholarly Interests Giant cell tumor of the bone
    Gastrointestinal stromal tumors
    Soft tissue sarcoma
    Osteosarcoma

  • Gerald Grant, MD, FACS

    Gerald Grant, MD, FACS

    Endowed Professor in Pediatric Neurosurgery and Professor, by courtesy, of Neurology at the Stanford University Medical Center

    Current Research and Scholarly Interests Dr. Grant directs a Blood-brain Barrier Translational Laboratory focusing on enhancing drug delivery to brain tumors in children.

  • Sigurdis Haraldsdottir

    Sigurdis Haraldsdottir

    Member, Stanford Cancer Institute

    Bio Dr. Sigurdis Haraldsdottir, M.D., Ph.D. is an Assistant Professor of Medicine at Stanford University School of Medicine. She received her medical degree and master's degree in medical sciences from the University of Iceland. She did her Internal Medicine training at Boston University Medical Center and training in Medical Oncology at the Ohio State University, before joining the faculty at Stanford. Her clinical and research focus is in gastrointestinal malignancies with a focus on mismatch repair deficient cancers, particularly colorectal cancer. She is conducting population-based research on Lynch syndrome - an inherited cancer syndrome, and recently completed a nation-wide study on Lynch syndrome in Iceland. She received her Ph.D. in Medical Sciences in 2017 from the University of Iceland. Her interests also focus on investigating colorectal cancer genomics, and their effect on outcomes and treatment implications.

  • Pehr Harbury

    Pehr Harbury

    Associate Professor of Biochemistry

    Current Research and Scholarly Interests Scientific breakthroughs often come on the heels of technological advances; advances that expose hidden truths of nature, and provide tools for engineering the world around us. Examples include the telescope (heliocentrism), the Michelson interferometer (relativity) and recombinant DNA (molecular evolution). Our lab explores innovative experimental approaches to problems in molecular biochemistry, focusing on technologies with the potential for broad impact.

  • Melanie Hayden Gephart

    Melanie Hayden Gephart

    Associate Professor of Neurosurgery and, by courtesy, of Neurology at the Stanford University Medical Center

    Bio I am a brain tumor neurosurgeon, treating patients with malignant and benign tumors, including glioma, brain metastases, meningioma, vestibular schwannoma, and pituitary adenomas. Our lab seeks greater understanding of the genetic and epigenetic mechanisms driving tumorigenesis and disease progression in malignant brain tumors. We currently study the capacity of cellular and cell-free nucleic acids to inform cancer biology and response to therapy. We also use single cell and cell subtype-specific transcriptomics to identify and target infiltrating glioblastoma. We use these techniques to identify mechanisms of tumor migration, and to stop tumor growth. Our laboratory is a unique and collaborative working environment, engaged in a dynamic research environment at Stanford. Our laboratory space lies at the heart of the Stanford campus between the core campus and the medical facilities, emblematic of the translational aspects of our work.

    www.GephartLab.com
    www.GBMseq.org

  • Chris Holsinger

    Chris Holsinger

    Professor of Otolaryngology - Head and Neck Surgery at the Stanford University Medical Center

    Current Research and Scholarly Interests Dr. Holsinger’s surgical practice focuses on the surgical management of benign and malignant diseases of the thyroid, parathyroid and head and neck.

    His areas of clinical interest include endoscopic head and neck surgery, including robotic thyroidectomy, transoral robotic surgery and transoral laser microsurgery, as well as time-honoured approaches of conservation laryngeal surgery, supracricoid partial laryngectomy.

  • Stefanie S. Jeffrey, MD

    Stefanie S. Jeffrey, MD

    John and Marva Warnock Professor

    Current Research and Scholarly Interests Dr. Jeffrey led the multidisciplinary team from the Schools of Medicine, Engineering, and Genome Technology Center that invented the MagSweeper, an automated device that immunomagnetically captures live circulating tumor cells (CTCs) from cancer patient blood for single cell analysis or culture. Her lab also works on microfluidic technologies for tumor cell capture, characterization, and growth - with the goal of defining individual patient response to newer biologically-based cancer therapies.